Riskpilot← Back to searchSign inGet full accessEP Endovascular AB
ABActiveOrg 5590134291Hans Michelsensgatan 2 BWholesale of pharmaceutical and medical goods · NACE 4646Est. 20150 employees
Revenue 2024
SEK 0
EBITDA margin
—
-58% vs 2023
Equity ratio
97.7%
Financial strength
Net profit 2024
SEK -42K
-68% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -38K | -58% |
| Net profit | SEK -42K | -68% |
| Total assets | SEK 240K | -81% |
| Equity | SEK 235K | -80% |
| Employees | 0 | — |
Legal name
EP Endovascular AB
Org number
5590134291
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
11 maj 2015
Share capital
SEK 200 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolagets verksamhet ska vara att bedriva distribution och tillverkning av medicintekniska produkter inom områdena perifier, neuro samt därmed förenlig verksamhet.
Address
Hans Michelsensgatan 2 B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 9 716 | 10 066 | 9 461 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 119 | 411 | 583 | −24 | −38 |
| Depreciation & amort. | −75 | −0 | −0 | −0 | — |
| EBIT | 44 | 411 | 583 | −24 | −38 |
| Net financials | −33 | −1 | — | −1 | −4 |
| Profit before tax | 12 | 409 | 583 | −25 | — |
| Tax | −4 | −86 | −120 | −0 | — |
| Net profit | 8 | 323 | 463 | −25 | −42 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 232 | 8 784 | 1 318 | 1 250 | 240 |
| Equity | 422 | 745 | 1 201 | 1 176 | 235 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 5 811 | 8 040 | 117 | 74 | 6 |
| Total debt | 5 811 | 8 040 | 117 | 74 | 6 |
EBITDA margin
-3784900.0%
This company
15.8%
Market median
-23955163% vs market
20202024
Equity ratio
97.7%
This company
38.2%
Market median
+156% vs market
20202024
Return on equity
-17.9%
This company
18.4%
Market median
-197% vs market
20202024
Net profit margin
-4199000.0%
This company
8.1%
Market median
-51839606% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CT Audit | Audit | 2021 |
SO Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (1) | ||
CP Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
UNIPHAR EUROPE LTD
EP Endovascular AB (this company)Board members of EP Endovascular AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Curt-Jörgen Per Petersson | Chief Executive Officer | 0 companies |
| Carl Teddie Leidhem | Audit | 0 companies |
| Seth Ola Patrick Mårtensson | Chief Executive Officer | 0 companies |
| Set Joakim Eriksson | Board of Directors | 0 companies |
| Padraic William Dempsey | Board of Directors | 0 companies |
| Timothy Dolphin | Chairman | 0 companies |
| Siobhan Brigid Taaffe | Board of Directors | 0 companies |